John W Regan, PhD

Professor, Pharmacology and Toxicology
Associate, Center for Toxicology
Professor, Neuroscience - GIDP
Phone Number: 
(520) 626-2181
Professional Bio: 

I am interested in how drugs work at the molecular level to either benefit or harm human health. This began with my graduate work at UC-Berkeley on drug metabolism in 1972 and has progressed through my professional career with extensive studies on the molecular pharmacology of the G-protein coupled receptors (GPCRs). The GPCRs are a large “superfamily” of receptors with over 800 members in the human genome. They are the primary target for the majority of drugs in use today and are central to understanding how drugs work.

From 1981-1989, I worked with Dr. Robert J. Lefkowitz at the Duke University Medical Center. During this time I studied the molecular pharmacology of the a2-adrenergic receptors, a member of the family of GPCRs. Like most GPCRs, until their molecular cloning the study of a2-receptors was exceptionally difficult due to their low natural abundance and the enormous purification needed for their isolation (~100,000 fold). However, together with Dr. Brian Kobilka, we achieved the first purification and cloning of this receptor protein in 1987. This was among the very first GPCR to be cloned, preceded only by the cloning of the b2-adrenergic and M1-muscarinic receptors in 1986. In total I published 25 papers with Drs. Lefkowitz and/or Kobilka and in 2012 they both received the Nobel Prize in Chemistry for their seminal contributions to the field of GPCRs. In their Nobel lectures, they both acknowledged my contributions to this body of work.

My laboratory at the University of Arizona is involved with studies of the molecular biology and signaling mechanisms of the prostanoid receptors, another subfamily of the GPCRs. Prostanoid receptors mediate the actions of the prostaglandins, which are hormonal substances that are involved with pain, fever and inflammation. Our studies of the prostanoid receptors led to the first cloning of the human EP2 receptor and to the cloning of the EP3 and FP receptor alternative splice variants. We have also characterized the activation of novel signaling pathways by these receptors involving phosphatidylinositol 3-kinase and elements of the Wnt signaling pathway. These findings have significance towards our understanding of cancer and other diseases.

Research Information

Research Program: 
Therapeutic Development
Research Focus: 

G-protein coupled receptors (GPCR) are integral membrane proteins that transduce extracellular hormonal signals from the plasma membrane to the interior of the cell. This large family of receptors is related both structurally and functionally. Structurally, GPCRs share a characteristic "seven transmembrane motif" which means that there are seven regions of the receptor that cross the plasma membrane. Functionally, GPCRs share the ability to interact with so-called ‘G-proteins’ following stimulation of the receptor by a hormonal signal. The G-proteins, or "guanine nucleotide binding regulatory proteins," lend their name to the GPCRs, but they actually represent a separate family of proteins. Upon stimulation of a GPCR by a hormonal signal one or more G-proteins are activated; which in turn activate additional families of proteins, which activate more proteins, etc. The end result of this is an increasing complex signaling cascade that culminates in a macroscopic response; e.g., muscle contraction, nerve depolarization, shape change, etc. The general interests of the Regan laboratory are to understand how drugs work by studying the molecular biology and signal transduction mechanisms of the G-protein coupled receptors (GPCRs). There are hundreds of different GPCRs; the ones under investigation in the Regan lab include the adrenergic and prostaglandin receptors that mediate the actions of adrenaline (epinephrine) and the prostaglandins, respectively. To study the GPCRs and their signal transduction pathways a variety of recombinant DNA approaches are utilized including the polymerase chain reaction (PCR), gene cloning, heterologous expression, and site-directed mutagenesis. In addition, functional approaches are employed such as the biochemical determination of second messenger function (e.g., protein phosphorylation, cAMP, calcium signaling) as well as immunofluorescence microscopy and real-time videomicroscopy. The goal of this work is to contribute to a better understanding of the GPCRs, their role in the biology of the cell, and their potential as targets for drug development.

Selected Publications: